Zobrazeno 1 - 10
of 26
pro vyhledávání: ''
Autor:
Grace Durenberger, Savannah C. Partridge, Vijayakrishna K. Gadi, Laura C Kennedy, Sasha E. Stanton, Shaveta Vinayak, Suzanne M. Dintzis
Publikováno v:
Journal of Clinical Oncology. 37:e14281-e14281
e14281 Background: Trastuzumab is an important drug in the treatment (tx) of HER2+ breast cancer, but not all tumors are responsive. Immune-enriched tumors have a better response to tx, and a biomarker to identify these tumors would be valuable. Mult
Autor:
Ashley Cimino-Mathews, Ashley Carpenter, Antonio C. Wolff, Christos Vaklavas, Vicente Valero, Roisin M. Connolly, Melissa Camp, Anna Maria Storniolo, Vered Stearns, Chiung Yu Huang, Jennifer M. Specht, Lisa A. Carey, Jeffrey P. Leal, Minetta C. Liu, Mothaffar F. Rimawi, Vandana G. Abramson, Lilja Solnes, Robert S. Miller, Katy Gaffney, Richard L. Wahl
Publikováno v:
Journal of Clinical Oncology. 36:511-511
511Background: Predictive biomarkers to identify patients with HER2-positive breast cancer (BC) that may be treated with targeted therapy alone are of great interest. We hypothesized that early cha...
Autor:
Martine Piccart-Gebhart, Gabriel N. Hortobagyi, Richard L. Theriault, Ana M. Gonzalez-Angulo, D. Larsimont, Vicente Valero, Florentia Peintinger, Aysegul A. Sahin, Fatima Cardoso, Heidi Stranzl, Ronjay Rakkhit, Kristine Broglio, Donald A Berry, Emer O Hanrahan, Peter M. Ravdin, Merih Guray, Thomas A. Buchholz, Funda Meric-Bernstam, Jennifer K. Litton, Francesco Feoli
Publikováno v:
Journal of Clinical Oncology. 27:5700-5706
Purpose To evaluate the risk of recurrence in women diagnosed with T1a and T1b, node-negative, human epidermal growth factor receptor 2 (HER2) –positive breast cancer. Methods We reviewed 965 T1a,bN0M0 breast cancers diagnosed at our institution be
Autor:
Kenneth Offit, Steven A. Narod
Publikováno v:
Journal of Clinical Oncology. 23:1656-1663
It has been 10 years since the BRCA1 gene was first identified. During this decade, genetic testing for breast cancer susceptibility has been incorporated into the practice of oncology. In this process, the identification of families at the highest h
Autor:
Tadeusz Pienkowski, Dennis J. Slamon, Ivonne Villalobos, Yanling Ma, John R. Mackey, Marc Buyse, Nicholas J. Robert, Vicente Valero, E. Quinaux, Wolfgang Eiermann, Denice D. Tsao-Wei, John Crown, Michael F. Press, Mary-Ann Lindsay, Guido Sauter, Martina Mirlacher, Miguel Martín, Hélène Fourmanoir, V. Bee-Munteanu, Anaamika Campeau
Publikováno v:
Journal of Clinical Oncology. 34:515-515
515Background: ASCO-CAP recently recommended further changes to evaluation of HER2 gene amplification by FISH. We retrospectively assessed the impact of the guidelines using annotated BCIRG-005, BCIRG-006, and BCIRG-007 clinical trial data for which
Autor:
Mohammed Salama, Alex Farr, Georg Pfeiler, Elisabeth Oppolzer, Zsuzsanna Bago-Horvath, Christian F. Singer, Michael Seifert, Myriam Weber
Publikováno v:
Journal of Clinical Oncology. 34:e12500-e12500
e12500Background: The proliferation marker Ki67 is an established prognostic and predictive marker in breast cancer. The association between Ki67 and treatment response in the neoadjuvant setting, however, is still unclear. We have therefore evaluate
Autor:
Norma O'Donovan, John Crown, Richard S. Finn, Michael J. Duffy, Dennis J. Slamon, Maeve Mullooly, Neil A. O'Brien, Dylan Conklin, Patricia M. McGowan
Publikováno v:
Journal of Clinical Oncology. 33:1099-1099
1099 Background: An urgent problem in breast cancer treatment is the identification and validation of a targeted therapy for triple-negative breast cancer (TNBC), ie, breast cancer negative for ER, PR and HER2. Neratinib is a low molecular weight irr
Publikováno v:
Journal of Clinical Oncology. 28:1809-1810
Breast cancer is a heterogeneous disease that is currently being classified into at least four main classes: basal-like, which is primarily progesterone receptor (PR) negative, estrogen receptor (ER) negative, and HER2 negative (ie, triple negative);
Publikováno v:
Journal of Clinical Oncology. 31:97-97
97 Background: Hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-positive tumors generally cluster within the luminal/HER2 subset; whereas HR-negative/HER2-positive tumors reside in HER2-enriched subset. We investigated w
Autor:
Edith A. Perez, Steven M. Butler, Nancy E. Davidson, Yan W. Asmann, Farid Jamshidian, Steven Shak, Karla V. Ballman, E. Aubrey Thompson, Peter A. Kaufman, Diana B. Cherbavaz, Frederick L. Baehner, Julie Gralow, Amylou C. Dueck
Publikováno v:
Journal of Clinical Oncology. 31:520-520
520 Background: There is considerable interest in developing HER2 testing criteria for adjuvant H. We used the 21-gene assay to examine the relationship of HER2 mRNA to benefit from H. Methods: N9831 compared adjuvant chemotherapy AC-T to concurrent